Caxton Associates LLP Invests $474,000 in Amicus Therapeutics, Inc. $FOLD

Key Points

• Caxton Associates LLP acquired a new position in Amicus Therapeutics with 58,114 shares valued at approximately $474,000 in the first quarter.
• Amicus Therapeutics shares opened at $8.02, and the stock has a market cap of $2.47 billion, while analysts maintain an average rating of "Moderate Buy" with a consensus target price of $16.00.
• Recent ratings changes show Morgan Stanley upgraded the stock to "overweight," while Wall Street Zen downgraded it from "buy" to "hold," reflecting mixed analyst sentiment.

Caxton Associates LLP purchased a new position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 58,114 shares of the biopharmaceutical company's stock, valued at approximately $474,000.

Other large investors also recently modified their holdings of the company. Virtus Fund Advisers LLC acquired a new stake in shares of Amicus Therapeutics during the fourth quarter valued at about $29,000. PNC Financial Services Group Inc. raised its holdings in Amicus Therapeutics by 211.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 5,151 shares of the biopharmaceutical company's stock valued at $42,000 after buying an additional 3,497 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Amicus Therapeutics during the 1st quarter worth approximately $53,000. GF Fund Management CO. LTD. bought a new stake in Amicus Therapeutics during the 4th quarter worth approximately $59,000. Finally, GAMMA Investing LLC increased its position in Amicus Therapeutics by 1,610.8% in the 1st quarter. GAMMA Investing LLC now owns 7,442 shares of the biopharmaceutical company's stock valued at $61,000 after acquiring an additional 7,007 shares during the period.

Amicus Therapeutics Stock Up 0.7%

NASDAQ FOLD traded up $0.06 during trading hours on Wednesday, hitting $8.07. The company's stock had a trading volume of 757,575 shares, compared to its average volume of 3,862,110. The company has a current ratio of 3.21, a quick ratio of 2.29 and a debt-to-equity ratio of 1.92. The company's 50-day simple moving average is $7.01 and its two-hundred day simple moving average is $6.98. The company has a market capitalization of $2.49 billion, a PE ratio of -67.45 and a beta of 0.55. Amicus Therapeutics, Inc. has a 52 week low of $5.51 and a 52 week high of $12.65.

Analyst Ratings Changes

FOLD has been the topic of several analyst reports. Morgan Stanley raised shares of Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research note on Thursday, July 17th. Wall Street Zen lowered Amicus Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, August 30th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company's stock. According to data from MarketBeat, Amicus Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $16.00.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.